Oregovomab and Nivolumab as a Combinatorial Immunotherapy Strategy for Recurrent Epithelial Ovarian Cance

Conference Correspondent —October 22, 2018


ESMO 2018

CA-125 is an antigen expressed on the surface of a variety of cancer cells, including 80% of advanced epithelial ovarian cancer (EOC), and is targeted by the monoclonal antibody oregovomab.1 Previous studies have shown that oregovomab is clinically active in EOC, and it has been hypothesized that combination with nivolumab, an anti–programmed cell death-1 (PD-1) inhibitor, may elicit a systemic CA-125–specific T-cell response that is synergistic, safe, and clinically efficacious in recurrent (rEOC) patients.

In the ORION-01 open-label, single-arm, phase 1b/2a study, Chan and colleagues treated patients who had received ≥2 prior chemotherapy lines for rEOC, fallopian tube, or primary peritoneal carcinoma with an initial dosage of oregovomab 2 mg every 4 weeks plus nivolumab 240 mg every 2 weeks. All 6 patients included in this study had EOC (4 high-grade serous, 2 clear cell) and had received a median of 4 (range, 3-9) treatment lines before starting the study. At the initial dosage, no dose-limiting toxicities (DLTs) were observed.

Treatment-related adverse events included grade 1 events of arthralgia, rash, transaminitis, fatigue, and anorexia. Two of 6 patients (33.3%) experienced grade 1 to grade 2 thyroid-related, immune-related adverse events. Five serious adverse events were observed but were deemed unlikely/not related to study treatment, including 2 episodes of grade 4 sepsis in 1 patient who eventually died of progressive disease.

In the current report,1 20 patients from the dose-finding and dose-expansion cohorts were treated at the recommended phase 2 dose (nivolumab 240 mg intravenously every 2 weeks + oregovomab 2 mg intravenously every 4 weeks). If DLT was observed after 3 patients, the dose of oregovomab could be cut in half, then halved again if DLT was observed again in another 3 patients. Between March 2017 and June 2017, 6 patients with EOC were recruited and treated at the top dose level. No DLT were observed. Treatment-related adverse events included grade 1 arthralgia, rash, transaminitis, fatigue, and anorexia; 2 of the 6 patients experienced grade 1 or 2 thyroid-related immune adverse events. Five serious adverse events were observed but were deemed unrelated to study treatment.

Given the results of this trial, the initial dosage used here of oregovomab 2 mg every 4 weeks plus nivolumab 240 mg every 2 weeks has been selected as the recommended dose for further study in recurrent epithelial ovarian cancer. Further evaluation of safety and efficacy of this novel combination is ongoing in the ORION-01 dose-expansion cohort.


  1. Chan JJ, et al. ESMO 2018. Abstract 979P.
Related Articles
A Meta-Analysis to Evaluate the Risk for Fatigue in Patients Treated with Olaparib for Advanced Cancer
Conference Correspondent
Fatigue and neuropathy were found to be common in patients treated with olaparib, and should be identified and managed early.
Initial Results from an Expansion Cohort Receiving Mirvetuximab Soravtansine/Pembrolizumab for Platinum-Resistant Ovarian Cancer: Initial Results from FORWARD II
Conference Correspondent
The antibody-drug conjugate mirvetuximab soravtansine combined with pembrolizumab has a manageable safety profile and encouraging signals of clinical activity.
Long-Term Tolerability of Olaparib Tablets as Maintenance Therapy for Platinum-Sensitive Relapsed Ovarian Cancer
Conference Correspondent
Similar to the capsule formulation, olaparib tablets have no cumulative toxicity, few late-onset adverse events, and a low rate of treatment discontinuation.
Last modified: October 22, 2018

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
  • Please enter your mailing address.

    Address Line 2
    Zip Code